Journal of Medical Economics
Volume 27, 2024 - Issue 1
Diabetes
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy
Annabel Barretta Eli Lilly and Company Ltd, Basingstoke, UKCorrespondence[email protected]
https://orcid.org/0009-0007-5510-448X
https://orcid.org/0009-0007-5510-448X, Kristina S. Boyeb Eli Lilly and Company, Indianapolis, IN, USAhttps://orcid.org/0000-0002-5953-5929
https://orcid.org/0000-0002-5953-5929, Luis-Emilio García-Pérezc Lilly S.A., Madrid, Spainhttps://orcid.org/0000-0003-3840-787X
https://orcid.org/0000-0003-3840-787X, , Bruno Guercie Department of Endocrinology, Diabetology & Nutrition, University Hospital of Nancy, Vandoeuvre Lès Nancy, Francehttps://orcid.org/0000-0002-6211-464X
https://orcid.org/0000-0002-6211-464X, , Maria Yug Eli Lilly Canada Inc, Toronto, ON, Canadahttps://orcid.org/0000-0003-1318-9052
https://orcid.org/0000-0003-1318-9052, , , , & show all